Back

Improved survival with around 5 years of continuous tafamidis treatment among patients with NYHA class III transthyretin amyloid cardiomyopathy

21 May 2022 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Pharmacology in heart failure - what is in horizon? Pharmacotherapy HFA Premium Access Heart Failure 2022

About the speaker

Photo
Doctor Pablo Garcia-Pavia

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Spain)

3 More presentations in this session

Presentation thumbnail
Outcomes of empagliflozin in patients with heart failure with a preserved ejection fraction and atrial fibrillation or atrial flutter: insights from EMPEROR-Preserved
Professor G. Filippatos (Athens, GR)
Abstract Slides
Presentation thumbnail
Intravenous infusion of the beta-3 adrenergic receptor antagonist APD418 improves left ventricular function in dogs with systolic heart failure despite long-term therapy with beta-blockers
Professor H. Sabbah (Detroit, US)
Abstract Slides
Presentation thumbnail
Eplerenone versus spironolactone and outcomes in patients with heart failure: a nationwide cohort study
Doctor J. Larsson (Copenhagen, DK)
Abstract Slides

Access the full session

Session thumbnail
Pharmacology in heart failure - what is in horizon?

The Event

Event poster

Heart Failure 2022

21 May - 24 May 2022
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources